ABBV
HealthcareAbbVie Inc.
$220.18
$-9.13 (-3.98%)
Jan 5, 2026
Price History (1Y)
Analysis
AbbVie Inc. is a healthcare company operating in the drug manufacturers-general industry within the healthcare sector. With a market capitalization of $389.14 billion, AbbVie is a large-scale entity with a significant presence in its industry. The company has approximately 55,000 employees. In terms of financial health, AbbVie demonstrates robust profitability, with gross margins reaching 71.5%, operating margins at 35.5%, and profit margins at 4.0%. Returns on equity (ROE) stand at 138.0%, while returns on assets (ROA) are at 9.6%. The company's balance sheet indicates a cash position of $5.67 billion, though its debt level is substantial at $68.85 billion. AbbVie's valuation context shows a P/E ratio of 172.02 (TTM), with a forward P/E of 15.45 and an EV/EBITDA of 15.87. Revenue growth year-over-year (YoY) stands at 9.1%, while earnings growth is significantly lower at -88.7%. The company's dividend yield is notably high, at 302.0%, with a payout ratio of 490.1%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Visit website →Key Statistics
- Market Cap
- $389.14B
- P/E Ratio
- 172.02
- 52-Week High
- $244.81
- 52-Week Low
- $164.39
- Avg Volume
- 5.47M
- Beta
- 0.35
- Dividend Yield
- 302.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NYQ
- Country
- United States
- Employees
- 55,000